共 280 条
- [1] Villanueva A(2019)Hepatocellular carcinoma N Engl J Med 380 1450-1462
- [2] Marrero JA(2018)Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases Hepatology 68 723-750
- [3] Kulik LM(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 391 1163-1173
- [4] Sirlin CB(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
- [5] Zhu AX(2017)Novel immune check point inhibiting antibodies in cancer therapy-opportunities and challenges Drug Resist Updat 30 39-47
- [6] Finn RS(2016)Targeting T cell co-receptors for cancer therapy Immunity 44 1069-1078
- [7] Abecassis MM(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-2502
- [8] Kudo M(2018)Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Lancet Oncol 19 940-952
- [9] Finn RS(2019)CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Ann Oncol 305 874-3392
- [10] Qin S(2019)Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs. best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC) J Clin Oncol. 37 4004-1405